Form 4: Aclaris Therapeutics Chief Business Officer James Loerop Reports Stock Transactions

Aclaris Therapeutics' Chief Business Officer, James Loerop, reported the acquisition and disposal of company stock and restricted stock units, including transactions to cover tax obligations.

Summary

• James Loerop, Chief Business Officer of Aclaris Therapeutics, reported several transactions involving the company's common stock and restricted stock units.
• On December 31, 2024, Mr. Loerop acquired 73,750 shares of common stock through the vesting of restricted stock units.
• Also on December 31, 2024, 32,089 shares were withheld to cover tax obligations related to the vesting of restricted stock units at a price of $2.48 per share.
• On January 2, 2025, Mr. Loerop acquired 18,150 shares of common stock through the vesting of restricted stock units.
• Additionally, on January 2, 2025, 8,575 shares were withheld to cover tax obligations at a price of $2.48 per share.
• Mr. Loerop's holdings of restricted stock units also changed, with 73,750 units vesting on December 31, 2024, and 55,000 units granted and 18,150 units vesting on January 2, 2025.
• The restricted stock units vest over time, with some vesting on December 31, 2024 and 2025, and others vesting on January 2, 2025, 2026, and 2027.

Sentiment

Score: 5

Explanation: The document is a routine filing of stock transactions by an executive, and does not indicate any positive or negative sentiment.

Positives

• The vesting of restricted stock units indicates that Mr. Loerop is meeting the conditions of his employment agreement.
• The acquisition of shares through vesting increases Mr. Loerop's stake in the company.

Negatives

• The disposal of shares to cover tax obligations reduces Mr. Loerop's overall shareholding.

Risks

• The transactions are routine and do not indicate any specific risks.
• The vesting schedule of the restricted stock units could be impacted by changes in employment status.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This is a standard SEC Form 4 filing, which is a routine disclosure for company insiders. It does not indicate any specific trends or competitive actions within the industry.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies, and the transactions reported are typical for executive compensation.
• The vesting schedules and tax withholding practices are common across the industry.
• There are no unusual or unexpected transactions reported in this filing when compared to similar filings from other companies.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation.
• The transactions do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Aclaris Therapeutics, James Loerop, stock transactions, restricted stock units, Form 4, insider trading, vesting, tax obligations